Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;26(1):141-9.
doi: 10.1080/10543406.2015.1092030.

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials

Anastasia Ivanova  1 , Barry Paul  2 , Olga Marchenko  3 , Guochen Song  3 , Neerali Patel  4 , Stergios J Moschos  2
Affiliations
Review

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials

Anastasia Ivanova et al. J Biopharm Stat. 2016.

Abstract

We investigated nine-year trends in statistical design and other features of Phase II oncology clinical trials published in 2005, 2010, and 2014 in five leading oncology journals: Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, and Lancet Oncology. The features analyzed included cancer type, multicenter vs. single-institution, statistical design, primary endpoint, number of treatment arms, number of patients per treatment arm, whether or not statistical methods were well described, whether the drug was found effective based on rigorous statistical testing of the null hypothesis, and whether the drug was recommended for future studies.

Keywords: Fleming’s design; Phase II trials; Simon’s design; oncology; two-stage design.

PubMed Disclaimer

References

    1. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. Journal of Clinical Oncology. 2010;28:1138–1144. - PMC - PubMed
    1. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994;50:1029–1041. - PubMed
    1. Bellissant E, Benichou J, Chastang C. Application of the triangular test to phase II cancer clinical trials. Statistics in Medicine. 1990;9:907–917. - PubMed
    1. Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, Luporsi E, Margueritte G, Lejars O, Laithier V, Mechinaud F, Millot F, Kalifa C, Chastagner P. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: Results of a French Society of Paediatric Oncology Phase II Study. Cancer. 2005;104:2792–2797. - PubMed
    1. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995;51:1372–1383. - PubMed

MeSH terms

Substances

LinkOut - more resources